Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma

European Journal of Cancer

Volumn 41, Issue 11, 2005, Pages 1645-1648

  O'Kane, S L ^a   Cawkwell, L ^a,c   Campbell, A ^b   Lind, M J ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

^b HULL ROYAL INFIRMARY   (United Kingdom)

^c CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

Cyclooxygenase; Immunohistochemistry; Mesothelioma

Indexed keywords

CYCLOOXYGENASE 2;

ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; EPITHELIUM CELL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MESOTHELIOMA; MULTIVARIATE ANALYSIS; PHENOTYPE; PLEURA MESOTHELIOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE PROTEINS; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; PROGNOSIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; REGRESSION ANALYSIS; SURVIVAL ANALYSIS;

EID: 22144439371     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.04.019     Document Type: Article

References (29)

1. J. Peto, J.T. Hodgson, and F.E. Matthews Continuing increase in mesothelioma mortality in Britain Lancet 345 1995 535 539
2. J. Peto, A. Decarli, and C. La Vecchia The European mesothelioma epidemic Br J Cancer 79 1999 666 672
3. M. Carbone, S. Fisher, and A. Powers New molecular and epidemiological issues in mesothelioma: role of SV40 J Cell Physiol 180 1999 167 172
4. D.W. Kamp, and S.A. Weitzman The molecular basis of asbestos induced lung injury Thorax 54 1999 638 652
5. K. Antman, R. Shemin, and L. Ryan Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Faber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985 J Clin Oncol 6 1988 147 153
6. N.J. Vogelzang, J.J. Rusthoven, and J. Symanowski Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma J Clin Oncol 21 2003 2636 2644
7. J.P. Steele Prognostic factors in mesothelioma Semin Oncol 29 2002 36 40
8. T. Van Gelder, R.A.M. Damhuis, and H.C. Hoogsteden Prognostic factors and survival in malignant pleural mesothelioma Eur Respir J 7 1994 1035 1038
9. L. Johansson, and C.J. Linden Aspects of histopathologic subtype as a prognostic factor in 85 pleural mesotheliomas Chest 109 1996 109 114
10. J.E. Herndon, M.R. Green, and A.P. Chahinian Factors predictive of survival among 337 patients treated between 1984 and 1994 by the Cancer and Leukemia Group B Chest 113 1998 723 731
11. T. Kawamori, C.V. Ravo, and K. Seilbert Chemopreventative activity of celecoxib, a specific cycooxygenase-2 inhibitor, against colon carcinogenesis Cancer Res 58 1998 409 412
12. G. Steinbach, and P.M. Lynch The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis New Engl J Med 342 2000 1946 1952
13. E.M. Funkhouser, and G.B. Sharp Aspirin and reduced risk of esophageal carcinoma Cancer 76 1995 1116 1119
14. N. Rioux, and A. Castonguay Prevention of NNK-induced lung tumourigenesis in A/J mice by acetylsalicylic caid and NS-398 Cancer Res 58 1998 5354 5360
15. J.E. Castelao, J.M. Yuan, and M. Gago-Dominguez Non-steroidal anti-inflammatory drugs and bladder cancer prevention Br J Cancer 82 2000 1364 1369
16. 1-dependent pathway Oncogene 21 2002 6113 6122
17. B. Agarwal, P. Swaroop, and P. Protiva Cox-2 is needed but not sufficient for apoptosis induced by Cox-2 selective inhibitors in colon cancer cells Apoptosis 8 2003 649 654
18. J.L. Masferrer, K.M. Leahy, and A.T. Koki Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors Cancer Res 60 2000 1306 1311
19. K. Uefuji, T. Ichkura, and H. Mochizuki Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer Clin Cancer Res 6 2000 135 138
20. M.M. Taketo Cyclooxygenase-2 inhibitors in tumorigenesis (part I) J Natl Cancer Inst 90 1998 1529 1536
21. M.M. Taketo Cyclooxygenase-2 inhibitors in tumorigenesis (part II) J Natl Cancer Inst 90 1998 1609 1620
22. J.G. Edwards, S.P. Faux, and S.M. Plummer Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma Clin Cancer Res 8 2002 1857 1862
23. A. Baldi, D. Santini, and F. Vasaturo Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma Thorax 59 2004 428 433
24. L. Cawkwell, S. Gray, and H. Murgatroyd Choice of management strategy for colorectal cancer based on a diagnostic immunohistochemical test for defective mismatch repair Gut 45 1999 409 415
25. A. Marrogi, H.I. Pass, and M. Khan Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): in vitro antiproliferative effects of a COX-2 inhibitor Cancer Res 60 2000 3696 3700
26. A.S. Cheng, H.L. Chan, and W.K. Leung Specific COX-2 inhibitor, NS-398, suppresses cellular proliferation and induces apoptosis in human hepatocellular carcinoma cells Int J Oncol 23 2003 113 119
27. M.P. Seed, C.N. Freemantle, and C.A. Alam Apoptosis induction and inhibition of colon-26 tumour growth and angiogenesis: findings on COX-1 and COX-2 inhibitors in vitro & in vivo and topical diclofenac in hyaluronan Adv Exp Med Biol 433 1997 339 342
28. H. Ito, M. Duxbury, and E. Benoit Fibronectin-induced COX-2 mediates MMP-2 expression and invasiveness of rhabdomyosarcoma Biochem Biophys Res Commun 318 2004 594 600
29. A. Catalano, L. Graciotti, and L. Rinaldi Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention Int J Cancer 109 2004 322 328